Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07140393CT.gov A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor | — | Not Yet Recruiting | — | — | — |
NCT06625775CT.gov Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06504732CT.gov To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer | — | Recruiting | — | — | — |
NCT06253871CT.gov A Phase 1/1b Study of IAM1363 in HER2 Cancers | — | Recruiting | — | — | — |
NCT07416409CT.gov Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer | — | Completed | — | — | — |
NCT05525858CT.gov KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | — | Recruiting | — | — | — |
NCT05159245CT.gov The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | — | Recruiting | — | — | — |
NCT04591431CT.gov The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | — | Unknown | — | — | — |
NCT03680560CT.gov Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | — | Terminated | — | — | — |
NCT03448042CT.gov A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | — | Active Not Recruiting | — | — | — |
Show 20 more trialsShow fewer
NCT03013218CT.gov A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | — | Completed | — | — | — |
NCT03006172CT.gov To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02932280CT.gov Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | — | Active Not Recruiting | — | — | — |
NCT03006614CT.gov PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer | — | Unknown | — | — | — |
NCT02627274CT.gov A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) | — | Completed | — | — | — |
NCT02593708CT.gov Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | — | Terminated | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT02277717CT.gov First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients | — | Completed | — | — | — |
NCT02091141CT.gov My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01971515CT.gov First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies | — | Completed | — | — | — |
NCT01771458CT.gov A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer | — | Completed | — | — | — |
NCT01235897CT.gov MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | — | Completed | — | — | — |
NCT00954512CT.gov Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | — | Terminated | — | — | — |
NCT00838539CT.gov Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors | — | Completed | — | — | — |
NCT00807859CT.gov Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00811993CT.gov A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT00847366CT.gov Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma | — | Completed | — | — | — |
NCT00397046CT.gov A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00300781CT.gov Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00803556CT.gov Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | Jiangsu HengRui Medicine Co., Ltd. | P3 | B · 58 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →